Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$11.21 USD

11.21
1,876,113

+0.04 (0.36%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $11.19 -0.02 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Dynavax Technologies Corporation [DVAX]

Reports for Purchase

Showing records 61 - 80 ( 121 total )

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 61

07/16/2020

Daily Note

Pages: 3

Collaboration With Mount Sinai to Develop a Universal Influenza Vaccine Candidate With CpG 1018 Adjuvant Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 62

07/14/2020

Daily Note

Pages: 3

First Participants Dosed in Phase 1 Trial Evaluating Medicago''s COVID-19 Vaccine Candidate With CpG 1018 Adjuvant

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 63

07/13/2020

Daily Note

Pages: 3

Dynavax and Times Pharmacy Partnership With Hep Free Hawaii Offering Heplisav-B in Oahu Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 64

07/08/2020

Daily Note

Pages: 3

COVID-19 Vaccine Collaboration With Medicago Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 65

06/26/2020

Company Report

Pages: 7

Highlights From HCW Virtual Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 66

06/19/2020

Daily Note

Pages: 3

First Patient Dosed in Phase 1 Trial Evaluating COVID-19 Vaccine Utilizing the CpG 1018 Adjuvant

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 67

06/09/2020

Daily Note

Pages: 3

Hemodialysis Trial Fully Enrolled

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 68

05/08/2020

Company Report

Pages: 6

1Q20 Results: Sales Above Our Estimate as No Pandemic Impact Seen Until End of March; Study Timelines Unchanged

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 69

04/29/2020

Daily Note

Pages: 3

Solid Interim Data from Trial Evaluating Heplisav- B in Hemodialysis Patients.

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 70

04/08/2020

Daily Note

Pages: 3

Dynavax Donates 10,000 Doses of Heplisav-B

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 71

04/03/2020

Company Report

Pages: 8

FY20 Heplisav-B Guidance Withdrawn Due to Pandemic

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 72

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 73

03/24/2020

Daily Note

Pages: 3

Another Collaboration to Develop a COVID-19 Vaccine

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 74

03/12/2020

Company Report

Pages: 6

4Q19 Results Below Expectations, but 2020 Sales Outlook Positive; Lowering PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 75

12/05/2019

Daily Note

Pages: 3

Dynavax Partners With Albertsons Companies

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 76

11/07/2019

Company Report

Pages: 6

3Q19 Results; Heplisav-B Sales Rise 22.4% Sequentially

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 77

10/18/2019

Company Report

Pages: 24

Initiating With a Buy Rating and $13 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 75.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 78

12/21/2012

Industry Report

Pages: 6

LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of December 23

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 79

05/11/2012

Company Report

Pages: 4

Dropping Coverage Due to Realignment of Research Coverage Since Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 80

04/12/2012

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party